Simulations Plus (SLP) – Investment Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Simulations Plus (NASDAQ: SLP) recently:

• 11/6/2024 – Simulations Plus had its “outperform” rating reaffirmed by analysts at William Blair.
• 11/4/2024 – Simulations Plus was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 10/24/2024 – Simulations Plus had its “outperform” rating reaffirmed by analysts at William Blair.
• 10/24/2024 – Simulations Plus had its price target lowered by analysts at BTIG Research from $60.00 to $50.00. They now have a “buy” rating on the stock.
• 9/12/2024 – Simulations Plus had its “outperform” rating reaffirmed by analysts at William Blair.

Simulations Plus Stock Performance

Shares of NASDAQ SLP opened at $30.59 on Monday. The business has a 50 day simple moving average of $31.60 and a 200 day simple moving average of $39.40. Simulations Plus, Inc. has a 52 week low of $27.22 and a 52 week high of $51.22. The stock has a market cap of $613.94 million, a price-to-earnings ratio of 62.43 and a beta of 0.71.

Simulations Plus (NASDAQ:SLP) last issued its earnings results on Wednesday, October 23rd. The technology company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The business had revenue of $18.70 million during the quarter, compared to analyst estimates of $19.73 million. During the same period in the prior year, the company posted $0.18 earnings per share. Simulations Plus’s revenue was up 19.9% on a year-over-year basis. On average, analysts predict that Simulations Plus, Inc. will post 1.12 EPS for the current year.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $35.18, for a total transaction of $703,600.00. Following the sale, the director now owns 3,501,592 shares of the company’s stock, valued at $123,186,006.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 60,750 shares of company stock valued at $1,905,655 over the last 90 days. 20.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Simulations Plus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SLP. Azzad Asset Management Inc. ADV raised its stake in Simulations Plus by 3.6% during the 2nd quarter. Azzad Asset Management Inc. ADV now owns 8,007 shares of the technology company’s stock worth $389,000 after buying an additional 280 shares during the period. InTrack Investment Management Inc increased its holdings in Simulations Plus by 1.1% during the 2nd quarter. InTrack Investment Management Inc now owns 31,665 shares of the technology company’s stock valued at $1,540,000 after purchasing an additional 330 shares during the period. First Horizon Advisors Inc. grew its holdings in shares of Simulations Plus by 82.6% during the 3rd quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock worth $26,000 after acquiring an additional 370 shares during the period. Chatham Capital Group Inc. lifted its position in Simulations Plus by 1.3% in the 2nd quarter. Chatham Capital Group Inc. now owns 34,554 shares of the technology company’s stock valued at $1,680,000 after acquiring an additional 450 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Simulations Plus by 7.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company’s stock valued at $311,000 after buying an additional 456 shares during the period. 78.08% of the stock is owned by institutional investors and hedge funds.

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.